Use of 5α-Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline

 Approved by the American Society of Clinical Oncology Board on July 21, 2008, and by the American Urological Association Board on October 17, 2008.

 This document is being reprinted as submitted without editorial or independent peer review by the Editors of The Journal of Urology®.

 This guideline was developed through a collaboration between the American Society of Clinical Oncology and the American Urological Association, and has been published jointly by invitation and consent in the Journal of Clinical Oncology and The Journal of Urology®. No part of this document may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording or any information storage and retrieval system, without written permission by the American Society of Clinical Oncology or the American Urological Association.

 See Editorial on page 1530.For another article on a related topic see page 1907.

PII: S0022-5347(09)00172-4

doi: 10.1016/j.juro.2009.01.071

© 2009 American Urological Association. Published by Elsevier Inc. All rights reserved.